Table 2.
Summary of clinical events in trials of oral anticoagulation versus antiplatelet treatment in patients with non-rheumatic atrial fibrillation
| Trial | No randomised | Fatal outcomes
|
Non-fatal outcomes
|
Other outcomes
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stroke | Vascular | All causes | Stroke | TIA | Thromboembolic | MI | Combined fatal and non-fatal* | Trial defined primary outcome | Major bleeds | ||||
| AFASAK 115 | |||||||||||||
| Warfarin | 335 | 1 | 3 | † | 4 | 0 | 0 | ¶ | 13‡ | 5 | 2§ | ||
| Aspirin | 336 | 3 | 12 | ¶ | 12 | 2 | 3 | ¶ | 30 | 20 | 1 | ||
| SPAF II <7517 | |||||||||||||
| Warfarin | 357 | 0 | 20 | 36 | 13 | 7 | 1 | 10 | 51 | 14 | 19 | ||
| Aspirin | 358 | 2 | 25 | 41 | 17 | 11 | 2 | 14 | 69 | 21 | 10 | ||
| SPAF II 75+17 | |||||||||||||
| Warfarin | 197 | 1 | 16 | 26 | 12 | 3 | 1 | 5 | 37 | 14 | 16 | ||
| Aspirin | 188 | 2 | 14 | 24 | 16 | 4 | 0 | 5 | 39 | 18 | 6 | ||
| AFASAK 216 | |||||||||||||
| Warfarin | 170 | 0 | 5 | 17 | 10 | 1 | 2 | 3 | 21 | 12 | 6 | ||
| Aspirin | 169 | 2 | 4 | 14 | 7 | 2 | 1 | 2 | 16 | 10 | 6 | ||
| SIFA18 | |||||||||||||
| Warfarin | 454 | 13 | 29 | 32 | 5 | ¶ | 5 | 2 | 41 | 41 | 4 | ||
| Indoprofen | 462 | 11 | 31 | 35 | 12 | ¶ | 4 | 2 | 49 | 49 | 0 | ||
| PATAF19 | |||||||||||||
| Warfarin | 131 | 0 | 9 | 12 | 3 | ¶ | 3 | 1 | 16 | 10 | 2 | ||
| Aspirin | 141 | 1 | 9 | 17 | 4 | ¶ | 4 | 2 | 19 | 12 | 11 | ||
*
Combined fatal and non-fatal outcomes comprise vascular deaths and all non-fatal vascular events.
†
No data presented but reported that there were no significant differences in vascular or total mortality in intention to treat analysis.
‡
Combined events do not total as six thromboembolic events in warfarin group and one in aspirin group occurred when patients were not taking treatment, which were not included in published main analyses. $Not all major bleeding events were reported. ¶Not reported.